Investor Relations

News Releases

<< Back
Nov 03, 2017
Intersect ENT to Present at the Piper Jaffray 29th Annual Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 3, 2017-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company’s business at the 29th Annual Piper Jaffray Healthcare Conference in New York.

The presentation is scheduled for 4:00pm ET on November 28, 2017, at the Lotte New York Palace in New York City.

A replay of the presentation will be available via the investors section of the company’s website at www.intersectENT.com. The webcast replay will be archived for approximately one month.

About Intersect ENT®

Intersect ENT is dedicated to transforming the landscape of care for patients with ear, nose and throat conditions. The company’s PROPEL® family of dissolvable steroid releasing sinus implants are clinically proven to improve outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost effective care.

For additional information on the company or the products including risks and benefits please visit www.IntersectENT.com.

Intersect ENT® and PROPEL® are registered trademarks and SINUVA is a trademark of Intersect ENT, Inc.

XENT-F

Source: Intersect ENT, Inc.

Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105
ir@intersectENT.com